AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17614188
Drug: Tooth mousse
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth mousse (CPP-ACP agent) applied on group A
Trial: 17614188
Drug: Tooth mousse
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth mousse (CPP-ACP agent) applied on group C
Trial: 17614188
Drug: No agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No agent applied on group B
Trial: 17614188
Drug: No agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No agent applied on group D
Trial: 16261661
Drug: Parenteral polyestradiol
RxNorm normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral polyestradiol phosphate (PEP) therapy (240 mg/month)
Trial: 12016597
Drug: Preoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative administration of morphine, ketamine, and clonidine (150 microg x kg(‐1) of morphine, 150 microg x kg(‐1) of ketamine, and 5 microg x kg(‐1) of clonidine)
Trial: 12016597
Drug: Postoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative administration of morphine, ketamine, and clonidine (150 microg x kg(‐1) of morphine, 150 microg x kg(‐1) of ketamine, and 5 microg x kg(‐1) of clonidine)
Trial: 30092782
Drug: Potassium excretion
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium excretion
Trial: 8821992
Drug: 1600 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 micrograms of inhaled beclomethasone dipropionate (BDP) daily for at least 3 months
Trial: 8821992
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of oral prednisolone for 3 weeks
Trial: 6289058
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg three times a day and 400 mg at night)
Trial: 26437056
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide 2 g/m2 + G-CSF (arm A)
Trial: 27485453
Drug: G-CSF alone
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF alone (arm B)
Trial: 21464679
Drug: 2-week supply
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week supply of nicotine patches
Trial: 21464679
Drug: 4-week supply
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week supply of nicotine patches
Trial: 21464679
Drug: 6-week supply
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week supply of nicotine patches
Trial: 10848721
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3.3% doxepin and 0.025% capsaicin
Trial: 9085951
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block (FNB) with 30 mL of 3% alkalinized chloroprocaine
Trial: 9085951
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 65 mg of 5% hyperbaric lidocaine
Trial: 8285849
Drug: Cyproterone acetate;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate; specific dosage and duration not mentioned
Trial: 3781705
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg three times daily for three weeks)
Trial: 24809884
Drug: Body Cream
RxNorm normalized name: Udderly Smooth Body Cream
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body Cream (Eucerin Eczema Relief Body Crème) applied twice daily for 14 days, followed by a 5-day regression period.
Trial: 24809884
Drug: Instant Therapy
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant Therapy (Eucerin Eczema Relief Instant Therapy) for active atopic dermatitis lesions administered for 14 days.
Trial: 7958119
Drug: Combination dose
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination dose aerosol of fenoterol hydrobromide (200 micrograms) and ipratropium bromide (80 micrograms)
Trial: 3314464
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg administered twice daily
Trial: 26573073
Drug: Prophylactic minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic minocycline (100 mg twice per day for 4 weeks)
Trial: 26573073
Drug: Reactive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive treatment (after rash developed, per grade of rash)
Trial: 26573073
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment unless severe (grade 3)
Trial: 24496086
Drug: Stellate ganglion
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stellate ganglion block (SGB) with 5 mL of 0.5% bupivacaine
Trial: 24496086
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection of saline
Trial: 22562434
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) with long-chain triglycerides (LCTs)
Trial: 12235653
Drug: Soy (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy (100 g/day)
Trial: 12235653
Drug: Tea extract
RxNorm normalized name: Tea Extract
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea extract (3 g/day)
Trial: 12235653
Drug: Vegetables (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetables (400 g/day as 134 g broccoli, 134 g brussels sprouts, and 134 g petits pois)
Trial: 12235653
Drug: High red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High red meat diet (420 g/day)
Trial: 10460065
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (200 mL, double-strength, three times a day for 2 days) with atorvastatin (40 mg)
Trial: 10460065
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (200 mL, double-strength, three times a day for 2 days) with pravastatin (40 mg)
Trial: 7543131
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diet and exercise advice (DE, n = 39)
Trial: 2523528
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg triamcinolone diacetate (TR)
Trial: 2523528
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of preservative-free morphine (MP)
Trial: 2523528
Drug: Both triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both triamcinolone and morphine (TR and MP)
Trial: 974610
Drug: Oxprenolol (beta-blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (beta-blocking agent)
Trial: 25751506
Drug: Seasonal WIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal WIV vaccine (sWIV) - one dose
Trial: 25751506
Drug: Pandemic WIV
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic WIV vaccine (pWIV) - two doses
Trial: 25751506
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available trivalent comparator vaccine - one dose followed by placebo
Trial: 19203569
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg test formulation of risperidone
Trial: 19203569
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg test formulation of risperidone
Trial: 19203569
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg reference formulation of risperidone
Trial: 19203569
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg reference formulation of risperidone
Trial: 17540193
Drug: Nesiritide (28-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesiritide (28-day continuous infusion)
Trial: 17540193
Drug: Placebo (28-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (28-day continuous infusion)
Trial: 15213581
Drug: Methylphenidate plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate plus psychosocial treatment (parent training, counseling, social skills training, psychotherapy, academic assistance)
Trial: 15213581
Drug: Methylphenidate plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate plus attention psychosocial control treatment
Trial: 11181810
Drug: Moxonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.2 mg twice a day)
Trial: 8220653
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg fluoxetine (FXT)
Trial: 8220653
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) breakfast (80 g maltodextrin, 300 kcal)
Trial: 3114812
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of physostigmine for 2 h
Trial: 30071838
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of at least three different classes of psychiatric drugs
Trial: 30071838
Drug: FGA alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGA alone therapy
Trial: 30071838
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of drugs from two different classes
Trial: 16847198
Drug: Psoralen-UV-A (PUVA)
RxNorm normalized name: Psoralen
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psoralen-UV-A (PUVA) therapy
Trial: 16847198
Drug: Narrowband UV-B
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband UV-B (NB-UVB) therapy
Trial: 8636825
Drug: Baseline cortisol
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline cortisol concentrations < 414 nmol/L (15.0 micrograms/dl)
Trial: 1473127
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (15 ml/d, equivalent to 3.1 g of n-3 fatty acid per day)
Trial: 1473127
Drug: Placebo (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (15 ml/d saline)
Trial: 28931520
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg HIV-MAG DNA vaccine coadministered with pIL-12 at 0, 250, 1,000, or 1,500 μg
Trial: 28931520
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg HIV-MAG DNA vaccine coadministered with pIL-12 at low and medium doses
Trial: 28931520
Drug: VSV-Gag vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSV-Gag vaccine boost
Trial: 28931520
Drug: DNA prime
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA prime with high-dose pIL-12
Trial: 28931520
Drug: High-dose pIL-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pIL-12 with DNA prime
Trial: 18775100
Drug: Flaxseed-derived lignan
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed-derived lignan capsules (360 mg/d)
Trial: 17243014
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control group (n=37)
Trial: 15770057
Drug: Ozonated autohemotherapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozonated autohemotherapy (ozone concentration of 50 microg/ml)
Trial: 7799018
Drug: Paclitaxel administered
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered at 135 mg/m2 by 3-hour infusion
Trial: 7799018
Drug: Paclitaxel administered
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered at 175 mg/m2 by 24-hour infusion
Trial: 7799018
Drug: Paclitaxel administered
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered at 225 mg/m2 by 3-hour infusion
Trial: 7799018
Drug: Duration that
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration that plasma concentrations of paclitaxel > or = 0.05 mumol/L
Trial: 2402844
Drug: Transcutaneous oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous oestradiol treatment
Trial: 31086034
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g enzymatically hydrolyzed collagen protein (EHC)
Trial: 31086034
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g non-enzymatically hydrolyzed collagen protein (NC)
Trial: 31086034
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mL water)
Trial: 23046782
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CT)
Trial: 11714591
Drug: Greater abstinence-specific
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater abstinence-specific structural support (fewer drug users in the social network)
Trial: 11714591
Drug: Decreases in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreases in negative abstinence-specific functional support (Complaints about Drug Use, Drug Exposure, and Demoralization)
Trial: 8993250
Drug: Heparin-coated cardiopulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated cardiopulmonary bypass surface (Duraflo II)
Trial: 8181028
Drug: Vasodilator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilator therapy (hydralazine-isosorbide dinitrate)
Trial: 2955799
Drug: Orgotein (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgotein (4 or 8 mg) injected 15 min after each daily radiation treatment
Trial: 2955799
Drug: Radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment (63 Gy in 30 fractions)
Trial: 24307502
Drug: Parenteral perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral perioperative antimicrobials (Group I)
Trial: 24307502
Drug: Extended oral
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended oral antimicrobials for 8 days postoperatively (Group II)
Trial: 22382787
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride capsule (20 mg, test)
Trial: 22382787
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride tablet (20 mg, reference)
Trial: 20560981
Drug: fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 160 mg daily for 8 weeks
Trial: 20560981
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment for 8 weeks (control)
Trial: 17556347
Drug: Time‐to‐treatment delay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time‐to‐treatment delay
Trial: 12407040
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg oral misoprostol twice daily (days 4-10)
Trial: 12407040
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg vaginal misoprostol and placebo
Trial: 7979285
Drug: Valaciclovir 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 1,000 mg four times daily for 30 days
Trial: 7979285
Drug: Valaciclovir 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 2,000 mg four times daily for 30 days
Trial: 3377946
Drug: Extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural morphine 3 mg
Trial: 3377946
Drug: Buprenorphine 0.18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.18 mg
Trial: 3377946
Drug: Buprenorphine 0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.09 mg
Trial: 3377946
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (morphine 3 mg, buprenorphine 0.18 mg, buprenorphine 0.09 mg)
Trial: 3377946
Drug: Morphine 3
RxNorm normalized name: apomorphine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 3 mg and buprenorphine 0.18 mg
Trial: 24337919
Drug: Invasive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive therapy (primary PCI)
Trial: 17551699
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg chlorazepate dipotassium (CD) in the evening and 25 mg CD in the morning, placebo 30 min prior to anesthesia
Trial: 17551699
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg midazolam on demand, placebo in the evening
Trial: 11452128
Drug: Activation of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activation of mu-opioid receptor system
Trial: 9452284
Drug: Artesunate suppositories
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate suppositories (15 mg/kg/day for three days)
Trial: 9452284
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (6 mg/kg/day for three days)
Trial: 7629484
Drug: Methimazole 60
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole 60 mg day‐1 combined with thyroxine
Trial: 7629484
Drug: Methimazole alone
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole alone (low-dose)
Trial: 7629484
Drug: Intention to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intention to treat analysis for high-dose group
Trial: 7629484
Drug: Intention to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intention to treat analysis for low-dose group
Trial: 2774647
Drug: Suspension-type ointment
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Suspension [Ipol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension-type ointment (0.0056% betamethasone-17-benzoate)
Trial: 2774647
Drug: Solution-type ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-type ointment (0.0056% betamethasone-17-benzoate)
Trial: 779588
Drug: Debrisoquine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debrisoquine (3 X 10 mg daily)
Trial: 779588
Drug: Methyldopa (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (3 X 250 mg daily)
Trial: 28838980
Drug: Fevipiprant 150
RxNorm normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fevipiprant 150 mg q.d
Trial: 28838980
Drug: Fevipiprant 75
RxNorm normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fevipiprant 75 mg b.i.d
Trial: 28838980
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg q.d
Trial: 21426664
Drug: Weekly usage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly usage of paclitaxel (45 mg/m², 1 time/week, total 270 mg/m² in 6 weeks)
Trial: 21426664
Drug: Triple weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple weekly usage of paclitaxel (15 mg/m², 3 times/week, total 270 mg/m² in 6 weeks)
Trial: 17876174
Drug: Enhanced decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced decision aid (previous digital rectal examination)